Mark Harding (center) of Cookstown was the second patient at Deborah Heart and Lung Center to receive the Parachute Ventricular Partitioning Device, as part of a new exciting clinical trial underway at the hospital. Deborah is the first investigational site to implant the device in New Jersey, New York, and eastern PA. The Parachute is a minimally-invasive treatment for patients with heart failure caused by damage to the heart muscle following a heart attack.
Through a catheter inserted in the femoral artery, the Parachute implant is deployed in the left ventricle to partition the damaged muscle, excluding the non-functional heart segment from the healthy, functional segment to decrease the overall volume of the left ventricle and restore its geometry and function.
Mr. Harding – a married National Guard employee with five grand-kids – was in good health until suffering a heart attack in July. Although he received two stents, his heart damage was causing him shortness of breath and leaving him exhausted, diminishing his quality of life.
“I want to feel better so that I can play ball with my grand-kids this summer,” he said.
Dr. Jon George, the cardiac interventionalist leading Mr. Harding’s implant team, is optimistic for him reaching this goal. “This is a promising new technology offering a great opportunity for patients suffering with heart failure after a heart attack.”